---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-25-001707"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:30:07.499763+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance

## Summary
- Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.
- Adjusted EBITDA improved to $(3.5)M from $(8.2)M; diluted EPS $(0.14) vs $(0.18) loss per share.
- Retail pharmacy revenue $75.9M, set fill records, contributed $12.8M gross profit.
- Fee-for-service revenue grew 13% YoY on organic growth in Florida and Oregon.
- Full year 2025 guidance raised (specific figures not disclosed in filed excerpt).

## SEC filing metadata
- accession: 0001079973-25-001707
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/0001079973-25-001707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001707/toi_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-25-001707
- JSON: https://secwatch.observer/filing/0001079973-25-001707.json
- Plain text: https://secwatch.observer/filing/0001079973-25-001707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.